Home › NCT06324396
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
RecruitingPhase 1
Who can join
Ages 8 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * \> 8 years * Status Post Fontan Completion * Ability to provide informed permission-assent (\<18 years) or consent (≥18 years) * Fasting overnight (\~8 hours) Exclusion Criteria: * Pregnancy * Non-fasting * Non-removable metal in body or where magnetic resonance imaging (MRI) is considered unsafe * Sildenafil and/or Pravastatin therapy within last 2 months * History of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter Sildenafil and Pravastatin disposition (absorption, metabolism, distribution, or clearance) * Pharmacotherapy that interacts with Sildenafil (cytochrome P450 3A4 and P450 3A5 (CYP3A4/5) inducers/inhibitors) and/or Pravastatin (organic anion transporting polypeptide (OATP1B1) inducers/inhibitors) * Inability to swallow a tablet * \>5X the age-specific upper limit of normal for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), total and conjugated bilirubin * Diarrhea in the last 24 hours \*History of solid organ transplantation
About the study
This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.
What is being tested
- Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) (drug)
- Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years) (drug)
Sponsor: Children's Mercy Hospital Kansas City · Participants: 15 · Started: Mar 1, 2024
Contact the study team
- Jonthan Wagner, DO · Phone: 816-731-7240
Official record on ClinicalTrials.gov — NCT06324396
Locations in the U.S.
| Missouri | Children's Mercy Hospital, Kansas City |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.